Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $128
10/1/2026
Impact: 70
Healthcare
Guggenheim analyst Subbu Nambi has maintained a Buy rating on BillionToOne (NASDAQ: BLLN) and increased the price target from $125 to $128.
AI summary, not financial advice
Share: